News for Cognetivity Neurosciences Ltd. (CGNSF)

Cognetivity Neurosciences Ltd.   , a leading AI healthcare technology company, is delighted to announce a collaboration with the Mediclinic Group , a prominent international private hospital group...

Cognetivity Neurosciences Ltd. reported earnings results for the second quarter and six months ended July 31, 2023. For the second quarter, the company reported sales was CAD 0.020284 million. Net...

Source: Stefan Quenneville July 6, 2023 (Investorideas.com Newswire) Despite having revenues below expectations, one analyst says this health company's Alzheim...

As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.

Share this article VANCOUVER- Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) , a technology company that has created a unique brain health...

A tech company responsible for creating a clinical testing platform that uses AI and machine learning for the detection of earliest cognitive impairment signs, Cognetivity Neurosciences Ltd.

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Revenues Reached Just Under $2.0 Million for the Quarter Ended October 31, 2021

VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited ("Ketamine One" or the "Company") (NEO: MEDI) (OTC: KONEF)